Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
NCT01078454
Completed
This randomized phase III trial is studying melphalan and dexamethasone to see how well they work with or without bortezomib in treating patients with previously untreated systemic amyloidosis. Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of plasma cells, either by killing the cells or by stopping them from dividing. Bortezomib may stop the growth of plasma cells by blocking some of the enzymes needed for cell growth. It is not yet kn... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2022
Locations: The Jewish Hospital, Cincinnati, Ohio +15 locations
Conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis
Register for Updates
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
NCT01109004
Completed
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus maintenance therapy versus the strategy of single autologous transplant plus consolidation therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy or single autologous transplant plus maintenance therapy as part of upfront treatment of multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in all arms.
Gender:
ALL
Ages:
70 years and below
Trial Updated:
12/08/2021
Locations: Jewish Hospital BMT Program, Cincinnati, Ohio +2 locations
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone in Cryptococcal Meningitis
NCT00000776
Completed
To evaluate the effect of corticosteroids on reducing elevated intracranial pressure in cryptococcal meningitis. To evaluate the safety of corticosteroids in patients with cryptococcal meningitis and intracranial hypertension. In AIDS patients with cryptococcal meningitis, a correlation has been found between early death and elevated intracranial pressure. Since dexamethasone has been found to reduce intracranial pressure resulting from other forms of meningitis, it may be of benefit in AIDS pa... Read More
Gender:
ALL
Ages:
13 years and above
Trial Updated:
10/27/2021
Locations: Ohio State Univ Hosp Clinic, Columbus, Ohio
Conditions: Meningitis, Cryptococcal, HIV Infections
Register for Updates
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
NCT00000658
Completed
To determine the impact of dose intensity on tumor response and survival in patients with HIV-associated non-Hodgkin's lymphoma (NHL). HIV-infected patients are at increased risk for developing intermediate and high-grade NHL. While combination chemotherapy for aggressive B-cell NHL in the absence of immunodeficiency is highly effective, the outcome of therapy for patients with AIDS-associated NHL has been disappointing. Treatment is frequently complicated by the occurrence of multiple opportun... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
10/26/2021
Locations: Case CRS, Cleveland, Ohio +1 locations
Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Register for Updates
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
NCT01412879
Completed
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy also work in different ways to kill more cancer cells or stop them from growing. It is not yet known whether rituximab is more effective with combination chemotherapy or bendamustine hydrochloride in treating patients wit... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/14/2021
Locations: Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center, Columbus, Ohio +26 locations
Conditions: Lymphoma
Register for Updates
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00651261
Unknown
The purpose of this study is to compare the effects, good and/or bad, of a standard chemotherapy regimen for AML that includes the drugs daunorubicin and cytarabine combined with or without midostaurin (also known as PKC412), to find out which is better. This research is being done because it is unknown whether the addition of midostaurin to chemotherapy treatment is better than chemotherapy treatment alone. Midostaurin has been tested in over 400 patients and is being studied in a number of ill... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
08/16/2021
Locations: Summa Center for Cancer Care at Akron City Hospital, Akron, Ohio +4 locations
Conditions: Leukemia
Register for Updates
Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone
NCT02516423
Unknown
This randomized phase III trial compares ixazomib citrate, lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well they work when given after radiation therapy in treating patients with solitary plasmacytoma of bone. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Dexamethasone is a drug used in chemotherapy that may ca... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2021
Locations: Indu and Raj Soin Medical Center, Beavercreek, Ohio +56 locations
Conditions: Solitary Osseous Plasmacytoma
Register for Updates
PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)
NCT01891643
Terminated
The purpose of the study is to look at subjects who receive Lenalidomide, Dexamethasone, and Elotuzumab and determine if they will have lower surface CS1 expression on malignant plasma cells at the time of progression than those who receive Lenalidomide and Dexamethasone without Elotuzumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2021
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma
Register for Updates
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00103285
Completed
This randomized phase III trial is studying different combination chemotherapy regimens and comparing how well they work in treating patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
06/11/2021
Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +9 locations
Conditions: Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Register for Updates
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
NCT02569320
Completed
This pilot phase I trial studies the side effects and best dose of histone deacetylase (HDAC) inhibitor AR-42 (AR-42) when given together with pomalidomide in treating patients with multiple myeloma that has returned after a period of improvement. HDAC inhibitor AR-42 may work to stop cancer growth by blocking an enzyme needed for cell growth. Pomalidomide is a drug used in chemotherapy that works to stop the growth of cancer cells by causing them to die. Giving HDAC inhibitor AR-42 together wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2021
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Recurrent Plasma Cell Myeloma
Register for Updates
A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
NCT03567616
Terminated
This was an open-label, multicenter study designed to evaluate the safety and preliminary efficacy of venetoclax combined with pomalidomide and dexamethasone in participants with relapsed or refractory (R/R) multiple myeloma (MM) who received at least 1 prior line of therapy with documented evidence of progression during or after the participant's last treatment regimen. The study was designed to consist of 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). For Part 2 the participant... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2021
Locations: Ohio State Cancer Center /ID# 202443, Columbus, Ohio
Conditions: Multiple Myeloma
Register for Updates
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
NCT00866307
Completed
This pilot clinical trial studies the side effects of pegaspargase when given together with combination chemotherapy in treating patients with newly diagnosed high-risk acute lymphoblastic leukemia. Pegaspargase may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more t... Read More
Gender:
ALL
Ages:
Between 1 year and 30 years
Trial Updated:
04/02/2021
Locations: Nationwide Children's Hospital, Columbus, Ohio +1 locations
Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Register for Updates